Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02554981 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®

A Phase 4 study of Dry Eye Syndromes, sponsored by Allergan.

Completed
Registry status
Phase 4
Development phase
51
Enrollment target
2
Study locations

NCT02554981 is a Phase 4 study of Dry Eye Syndromes that has completed, run by Allergan. The registered enrollment target is 51 participants, below the 411-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02554981, a Phase 4 study of Dry Eye Syndromes, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 4
Development phase
51 participants
Enrollment target
2
Study locations

Study Summary

This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.

Conditions Studied

Interventions

  • DRUG Cyclosporine 0.05% Ophthalmic Emulsion

Study Locations (2)

Massachusetts

  • Andover Eye Associates, Inc - Andover

Tennessee

  • Total Eye Care, PA - Memphis

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2015-07-21
Est. Completion 2016-03-24
Phase Phase 4

Sponsor

Allergan

314 total trials

What the Registry Record Tells You About NCT02554981

The ClinicalTrials.gov registry entry for NCT02554981 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 411-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (88% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Cyclosporine 0.05% Ophthalmic Emulsion is the first listed.

NCT02554981 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Tennessee.

Frequently Asked Questions

What is clinical trial NCT02554981 about?

NCT02554981 is a clinical study titled "Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®". This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.

What is the current status of trial NCT02554981?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2015-07-21. Estimated completion is 2016-03-24.

What conditions does trial NCT02554981 study?

This clinical trial studies the following conditions: Dry Eye Syndromes.

What interventions are being tested in trial NCT02554981?

The interventions under investigation include: Cyclosporine 0.05% Ophthalmic Emulsion (DRUG).

Who is sponsoring clinical trial NCT02554981?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02554981 being conducted?

This trial has 2 study locations across Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.